LCTXLineage Cell Therapeutics, Inc.同业对比
Lineage Cell Therapeutics, Inc. 与SIC 2836 行业的逐项对比:市值、估值、增长、盈利能力、质量与总回报,以及在同业组内的排名。所有数值均由引擎从 SEC 申报与延迟行情计算,排名仅为组内排序位置 —— 描述性数据,非投资建议。
完整同业对比
同业组:同 SIC 行业分类 | 公司 | 市值 | 市盈率(TTM) | 市净率 | 市销率 | 营收同比增长 | 净利同比增长 | 息税前利润率 | 净资产收益率 | 投入资本回报率 | 皮氏 F 值 | 一年总回报 | 股息率 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| LCTX本股 | $258M#8 | — | 4.2x#12 | 17.7x#6 | 53.2%#3 | -241.4%#13 | -251.6%#5 | -104.3%#12 | — | — | -47.8%#9 | — |
| KYTX | $319M#1 | — | 1.9x#9 | — | — | -26.5%#9 | — | -97.4%#11 | -107.1%#4 | — | -25.1%#7 | — |
| XFOR | $313M#2 | 2.2x#2 | 2.0x#10 | 8.9x#4 | 1273.2%#2 | -111.5%#12 | -247.4%#4 | -50.9%#8 | -582.0%#5 | — | -22.8%#6 | — |
| SCTX | $308M#3 | — | — | — | — | — | — | — | — | — | — | — |
| AGEN | $301M#4 | 2.2x#3 | — | 2.6x#2 | 10.4%#4 | 98.7%#2 | -17.7%#3 | — | — | — | — | — |
| EIKN | $300M#5 | — | 0.6x#1 | — | — | — | — | 0.0%#2 | — | — | — | — |
| SABS | $285M#6 | 13.0x#5 | 1.3x#5 | — | -100.0%#9 | 138.9%#1 | — | 6.2%#1 | — | — | — | — |
| IPSC | $274M#7 | — | 1.2x#4 | 2.5x#1 | 1556.8%#1 | 92.4%#3 | -15.8%#2 | -4.1%#3 | -9.3%#1 | — | 152.6%#1 | — |
| OCGN | $258M#9 | — | — | 58.4x#8 | 8.8%#5 | -25.9%#8 | -1425.7%#7 | — | — | — | -50.2%#10 | — |
| LXEO | $257M#10 | — | 1.1x#2 | 393.3x#9 | — | -1.7%#5 | -16706.0%#9 | -42.5%#7 | — | — | -65.3%#12 | — |
| FATE | $245M#11 | — | 1.6x#7 | 36.9x#7 | -51.2%#7 | 26.8%#4 | -2222.4%#8 | -88.8%#10 | -102.3%#3 | — | 62.9%#2 | — |
| CABA | $242M#12 | — | 1.2x#3 | — | — | -44.9%#10 | — | -79.7%#9 | — | — | -52.3%#11 | — |
| ALEC | $230M#13 | — | — | 10.9x#5 | -79.1%#8 | -20.2%#7 | -741.3%#6 | — | — | — | 42.1%#3 | — |
| PALI | $216M#14 | 1.9x#1 | 1.8x#8 | — | — | -16.2%#6 | — | -13.8%#5 | — | — | -37.8%#8 | — |
| PLX | $209M#15 | 11.3x#4 | 2.9x#11 | 4.0x#3 | -1.2%#6 | -325.2%#14 | -10.4%#1 | -9.2%#4 | -12.3%#2 | 3#1 | 9.3%#4 | — |
| IKT | $208M#16 | — | 1.4x#6 | — | -100.0%#9 | -75.4%#11 | — | -31.5%#6 | — | — | -8.0%#5 | — |
数值来自 SEC 申报与延迟行情;排名仅为该组内的排序位置 —— 描述性数据,不构成评级或建议。 本表构建超时,仅覆盖该组的一部分成员;排名仅相对于已列出的行,稍后会自动补全。 数据构建于 2026-11-04。
数据来自 SEC XBRL 申报与延迟行情 · 排名为组内排序 · 仅供参考 · 非投资建议